Scleroderma Healthcare Report
Sclerodermie Advies & Voorlichting (Scleroderma Recommendation & Information – SAV) initiated the Scleroderma Healthcare study in 2013.
The principal reason was that the owner of SAV, Ramona Kanters, suffers from this disease and has made it her life objective to improve healthcare and quality of life in scleroderma. In this setting up to 200 patients were interviewed and the team administered a questionnaire.
The questionnaires were analyzed for 65 of these patients, 59 female and 6 male.
Read the whole report by Ramona Kanters and Mieke Rovers.
For more information, please visit the Sclerodermie Advies & Voorlichting website.
news & events
Watch our highlights video showing some of our great achievements in 2022.
Are you living with diffuse scleroderma?
Would you like to be involved in a clinical study testing a new investigational drug for use in Diffuse Scleroderma?
If so, you may be eligible to take part in the DECODE Scleroderma Study
FESCA is proud to be a partner of a the new This is Living campaign launched last month by Boehringer Ingelheim.